Baclofen is an agonist of the amino-butyricum B (GABA-B) receptor used for a long time in neurology to treat spastic contracture. Several clinical studies have suggested its efficacy in the treatment of alcohol-dependence in low, even in case of cirrhosis and high dose. French drug authority has authorized its use in 2012 whereas the l'European Association for the Study of the Liver recommends to perform additional studies on this indication. The goal of this observational study is to evaluate the use of baclofen for alcohol-dependence in real life care as well its efficacy.
Numerous centers of the French research group of the national association of the hepatologists and gastroenterologists from general hospitals (ANGH) will be part of this study. Patients treated with baclofen for alcohol -dependence will be enroll prospectively from 2014 and retrospectively if they were treated between 2012 and 2014. The reported alcohol consumption, biological markers of excessive alcohol, initial and usual baclofen dosage, blood balofen dosage as well as clinical data will be collected.
Study Type
OBSERVATIONAL
Enrollment
218
Centre hospitalier yves LEFOLL
Saint-Brieuc, Côtes d'Armor, France
Centre Hospitalier Régional Universitaire Hôpital Jean Minjoz
Besançon, Franche-Comté, France
CH Béziers
Béziers, Hérault, France
CH Orleans
Orléans, Loiret, France
GHPSO Creil-Senlis
Creil, Oise, France
CH meaux
Meaux, Seine Et Marne, France
CHI CRETEIL addictology
Créteil, France
Hôpital saint denis
Saint-Denis, Île-de-France Region, France
Target population
Demographic and clinical characteristics of patients who take baclofen for alcohol addiction: mean age, alcohol consumption, child pugh score, etc.
Time frame: at inclusion
baclofen posology
used baclofen posology will be recorded to determine the posology scheme to treat patients with or without cirrhosis
Time frame: at inclusion, at 3, 6 and 12 months of follow-up
Alcohol consumption
Evolution of the alcohol consumption in patients under baclofen therapy
Time frame: at inclusion, at 3, 6 and 12 months of follow-up
Biological markers of alcohol consumption
Evolution of the biological markers of alcohol consumption in patients under baclofen therapy
Time frame: at inclusion, at 3, 6 and 12 months of follow-up
baclofen tolerance
Description of the side effects under baclofen therapy
Time frame: at 3, 6 and 12 months of follow-up
Baclofen dosage
Blood baclofen dosage under baclofen treatment, if available
Time frame: at 3, 6 and 12 months of follow-up
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.